169 related articles for article (PubMed ID: 36676701)
1. Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy.
Lee E; Kang MK; Moon G; Gu MJ
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676701
[TBL] [Abstract][Full Text] [Related]
2. Primary diffuse large B-cell lymphoma of the Larynx.
Higo R; Kojima M; Itoh S; Noguchi M; Izumi H; Takeuchi K
Auris Nasus Larynx; 2023 Aug; 50(4):632-636. PubMed ID: 35863932
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
4. Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report.
Jia N; Tang Y; Li Y
Medicine (Baltimore); 2020 Feb; 99(6):e18590. PubMed ID: 32028388
[TBL] [Abstract][Full Text] [Related]
5. Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma.
Kilani Y; Sohail H; Lim CY; Payette A; Kamal SAF; Afzal A; Khan T; Paracha N; Muppidi MR; Sittler D
Am J Case Rep; 2022 Sep; 23():e937500. PubMed ID: 36151707
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
10. [Rupture of hepatic lesion of diffuse large B-cell lymphoma following immunochemotherapy].
Segawa R; Natazuka T
Rinsho Ketsueki; 2022; 63(3):211-216. PubMed ID: 35387935
[TBL] [Abstract][Full Text] [Related]
11. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphoma in the maxilla: A case report.
Zou H; Yang H; Zou Y; Lei L; Song L
Medicine (Baltimore); 2018 May; 97(20):e10707. PubMed ID: 29768336
[TBL] [Abstract][Full Text] [Related]
13. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.
Zheng SM; Zhou DJ; Chen YH; Jiang R; Wang YX; Zhang Y; Xue HL; Wang HQ; Mou D; Zeng WZ
World J Gastroenterol; 2017 Jun; 23(24):4467-4472. PubMed ID: 28706431
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
17. Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: case report and review of literature.
Lakshmaiah KC; Viveka BK; Anil Kumar N; Saini ML; Sinha S; Saini KS
J Egypt Natl Canc Inst; 2013 Dec; 25(4):231-5. PubMed ID: 24207096
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
